LKT Laboratories, Inc.

Fluvastatin Sodium

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID F4482
CAS No. 93957-55-2
Chemical Name (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methyl- ethyl)-1H-indol-2-yl] -3,5-dihydroxy-6-heptenoic acid sodium salt
Synonym Fluindostatin, XU-62-320, Lescol, Lipaxan, Primexin



Formula $C_{24}H_{25}FNNaO_4$
Formula Wt. 433.45
Melting Point 194-197°C
Purity ≥98%
Solubility Soluble in water (50 mM), methanol, ethanol, and DMSO (100 mM)

Bulk quanitites available upon request

Product ID	Size
F4482	10 mg
F4482	50 mg
F4482	100 mg

Store Temp Ambient
Ship Temp Ambient

Description Fluvastatin is an inhibitor of HMG-CoA reductase that is clinically used to lower cholesterol and treat cardiovascular disease. Fluvastatin exhibits anti-hyperlipidemic, anti-fibrotic, cardioprotective, antiviral, antithrombotic, antioxidative, vasorelaxant, anti-atherosclerotic, and anticancer activities. Fluvastatin suppresses viral load of hepatitis C virus in a clinical setting and prevents viral replication. In vitro, fluvastatin decreases platelet activation by increasing PECAM-1 signaling and inhibiting activation of Akt. Additionally, fluvastatin scavenges hydroxyl radicals in vitro. In other cellular models, fluvastatin increases expression of NO and phospholipase 2 (PLA2) and decreases levels of angiotensin II (AT II) and ROCK. Additionally, this compound induces apoptosis and G2/M phase cell cycle arrest, decreases the mitochondrial membrane potential, and increases release of cytochrome c and activation of caspase 3 in hepatocellular carcinoma cells. In animal models of cardiac distress, fluvastatin improves left ventricular function and prevent fibrosis by inhibiting RhoA and decreasing levels of CTFG and fibronectin.

References

Wuestenberg A, Kah J, Singethan K, et al. Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin. PLoS One. 2014 May 6;9(5):e96533. PMID: 24801208.

Moraes LA, Vaiyapuri S, Sasikumar P, et al. Antithrombotic actions of statins involve PECAM-1 signaling. Blood. 2013 Oct 31;122 (18):3188-96. PMID: 24030383.

Vandjelovic N, Zhu H, Misra HP, et al. EPR studies on hydroxyl radical-scavenging activities of pravastatin and fluvastatin. Mol Cell Biochem. 2012 May;364(1-2):71-7. PMID: 22207075.

Yaktubay Döndaş N, Sucu N, Coşkun Yilmaz B, et al. Molecular mechanism of vasorelaxant and antiatherogenic effects of the statins in the human saphenous vein graft. Eur J Pharmacol. 2011 Sep;666(1-3):150-7. PMID: 21620829.

Dai QM, Lu J, Liu NF. Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor. Chin Med J (Engl). 2011 Jan;124(1):89-94. PMID: 21362314.

Zhang W, Wu J, Zhou L, et al. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol. 2010 Dec;48(12):1167-74. PMID: 21250597.

Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008;47(7):463-74. PMID: 18563955.